Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3
Healthcare stocks UTHR, COLL and AHG show oversold RSI levels near or below 30, potentially offering undervalued buying opportunities.
BenzingayesterdayCOLL
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.
Benzinga16 days agoCOLL
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43
Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.
Benzinga28 days agoCOLL
Collegium Pharmaceutical, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Collegium Pharmaceutical, Inc.
SeekingAlpha28 days agoCOLL
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsIan Karp - Head of Investor RelationsVikram...
SeekingAlpha29 days agoCOLL
Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $46
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $56 to $46.
Benzinga29 days agoCOLL
Collegium Pharmaceutical (NASDAQ:COLL) Tumbles on Revenue Miss and Lowered Guidance
Collegium Pharma Q2 beats EPS but misses revenue; cuts FY product revenue guidance, stock falls ~11%. ADHD growth offsets pain portfolio weakness.
ChartMill29 days agoCOLL
Collegium Pharmaceutical Lowers FY2026 Sales Guidance from $865.000M-$895.000M to $825.000M-$855.000M vs $872.278M Est
Collegium Pharmaceutical (NASDAQ:COLL) lowers FY2026 sales outlook from $865.000 million-$895.000 million to $825.000 million-$855.000 million vs $872.278 million estimate.
Benzinga29 days agoCOLL